Short vs longer infusion antibiotic for ventilator lung infection
Part of Infections, Lungs & breathing clinical trials.
This Phase 3 study compares a shorter vs longer drip schedule of the antibiotic ceftolozane-tazobactam in ICU patients with a specific type of ventilator-associated pneumonia caused by Pseudomonas. It aims to find which infusion time works as well (or better) while treating the infection safely.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have ventilator-associated pneumonia caused by Pseudomonas aeruginosa
- You’re being treated in an intensive care unit (ICU)
- The bacteria strain can be treated with ceftolozane-tazobactam (test shows susceptibility)
- You’re very sick but expected to live more than 7 days (SAPS II score over 20)
- You can give consent, or a close trusted person can help consent for you
- You must not have major kidney limits (CKD-EPI kidney filtering rate under 50) or be on dialysis
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an antibiotic called ceftazidime-avibactam for people with serious infections like bloodstream infections or pneumonia that started in the hospital or from a breathing machine. It aims to start treatment quickly after identifying the bacteria.
This trial tests an “antibiotic stewardship” approach—choosing and adjusting antibiotics in a smarter way—for a first episode of pneumonia in patients on a breathing machine. It may help ensure the right antibiotics are used at the right time, while avoiding unnecessary or overly broad treatment.
This trial tests whether switching from an initial antibiotic to cotrimoxazole (a specific antibiotic combination) can work as well—or better—for ventilator-associated pneumonia in ICU patients. It aims to see if “de-escalating” antibiotics can control the infection while keeping vital signs stable.
This trial tests if an inhaled antibiotic (amikacin) can treat an infection in the breathing tube (ventilator-associated tracheobronchitis) better than a placebo. You may qualify if you are on a ventilator and have this type of infection.
This trial tests whether using a fast respiratory test combined with a treatment plan can help doctors choose the right antibiotics sooner for patients in the intensive care unit who get pneumonia from a breathing machine. It aims to improve treatment and reduce unnecessary antibiotics.
This trial tests two ways of giving the antibiotic ceftazidime/avibactam (a powerful drug for resistant bacteria) to critically ill patients in the ICU. The goal is to see if a continuous infusion works better than standard timed doses.
Hear when a new Ventilator Associated Pneumonia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.